Spero Therapeutics, Inc.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company whose core business of developing novel antibacterial treatments necessitates animal testing as part of the drug development process. The company's pipeline candidates, including SPR994 (tebipenem HBr) and SPR720, have progressed through preclinical stages involving animal studies to evaluate efficacy and safety, a standard requirement for regulatory approval of new chemical entities.

Specific research documents detail this reliance on animal models. For instance, a 2024 study on SPR720 published in a scientific journal explicitly notes its "efficacy... in murine models," indicating the use of mice in its development program. Similarly, company filings reference the completion of "preclinical laboratory tests [and] animal studies" as part of its development workflow. As a pharmaceutical company seeking FDA approval for its products, Spero Therapeutics conducts, funds, and relies upon animal testing to advance its clinical assets toward commercialization.